Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDE study of fluorescent adalimumab tracer imaging in inflammatory bowel disease
NL-OMON59622Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab-680LT, adalimumab in inflammatory bowel disease (IBD), autoimmune colitis, Crohn's disease, sponsored by University Medical Center Groningen. Started Mar 2024; status: completed.
02
Drugs
adalimumab-680LTadalimumab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON59622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59622.